

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/16, C07C 39/06, 39/12, 39/17		A2	(11) International Publication Number: WO 97/10800 (43) International Publication Date: 27 March 1997 (27.03.97)
(21) International Application Number: PCT/US96/15017 (22) International Filing Date: 18 September 1996 (18.09.96) (30) Priority Data: 60/004,196 22 September 1995 (22.09.95) US (71) Applicant: COLGATE-PALMOLIVE COMPANY [US/US]; 300 Park Avenue, New York, NY 10022 (US). (72) Inventors: STRINGER, Orum, D.; 1109 Gloria Lane, Yardley, PA 19067 (US). BRAHMS, John, C.; Apartment B2, 222 Sullivan Way, Trenton, NJ 08628 (US). SUBRAMANIAN, Malathy; 20 Champions Circle, Branchburg, NJ 08876 (US). KELLY, Ernest, E.; 81 South Ward Street, New Brunswick, NJ 08901 (US). (74) Agent: STONE, Robert, L.; Colgate-Palmolive Company, 909 River Road, Piscataway, NJ 08855-1343 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ANTIPLAQUE ORAL COMPOSITION			
(57) Abstract An oral antiplaque composition and treatment of teeth therewith wherein the essential antiplaque agent is a substantially water insoluble noncationic antibacterial phenol containing, relative to the hydroxyl group, an alkyl or cycloalkyl group, preferably tert.-butyl(t-butyl), in 2-position, and substituents in one or both of the 4- and 5-positions, one of which may be phenyl or 2',3' and/or 4' substituted alkyl or cycloalkyl phenyl, preferably 4'-t-butyl phenyl, or one or both of the 4- and 5- substituents may be alkyl or cycloalkyl, one being preferably t-butyl, or a phenanthrene containing a hydroxyl substituent in the 2- or 3-positions and alkyl or cycloalkyl, preferably t-butyl, substituents in the other of the 2- and 3-positions and in at least one of the other rings. Novel antibacterial alkylated phenols.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

ANTIPLAQUE ORAL COMPOSITION

5

This invention relates to antibacterial antiplaque oral compositions and also to compositions containing a novel essential antiplaque component comprising a substantially water insoluble, noncationic antibacterial alkylated phenol compound more fully described below and to a selected group of such compounds which are considered novel.

10

Dental plaque is a soft deposit which forms on teeth as opposed to calculus which is a hard calcified deposit on teeth. Unlike calculus, plaque may form on any part of the tooth surface, particularly including at the gingival margin. Hence, beside being unsightly, it is implicated in the occurrence of gingivitis.

15

Accordingly, it is highly desirable to include antimicrobial (antibacterial) agents which have been known to reduce plaque in oral compositions.

20

The cationic antibacterial materials such as chlorhexidine, benzthonium chloride and cetyl pyridinium chloride have been the subject of greatest investigation as antibacterial antiplaque agents. However, they are generally not effective when used with anionic materials. Noncationic antibacterial materials, on the other hand, can be compatible with anionic components in an oral composition.

25

However, oral compositions typically are mixtures of numerous components and even such typically neutral materials as humectants can affect performance of such compositions.

30

Halogenated hydroxydiphenyl ethers such as triclosan have been very effectively employed in oral compositions as antibacterial antiplaque agents. However, it is desirable to be able to provide non-halogenated agents which are highly effective and possibly even more effective than triclosan.

35

Phenol and alkyl substituted phenols are well known and widely used antimicrobials. Thymol (2-isopropyl-5-methylphenol) is an active antimicrobial agent in commercial mouthrinse formulations, but its anti-microbial activity is considered relatively low and possibly insufficient, its activity for example being only a small

fraction of the activity of triclosan . Hitherto, alternatives to triclosan having substantially greater antiplaque activity than thymol or than monoalkyl phenols and optimally comparable to or even greater than the activity of triclosan have not been available.

5


It is an object of this invention to provide an antiplaque oral composition with substantial antiplaque effectiveness containing noncationic phenolic oral antibacterial antiplaque agents (AA) as alternatives to triclosan . Another object is to provide alkyl phenolic AA's which, except for the single OH group, are entirely hydrocarbon and which have oral antimicrobial activities up to 100 or more times the activity of thymol, for instance up to as much as or exceeding the activity of triclosan. A further object is to provide such AA's which are, or can be expected to be, found in nature, e.g. plant material, etc. Still another object is to provide novel AA's. Other objects and advantages will appear as the description proceeds.

10
15


In accordance with some of its aspects, this invention relates to an oral antiplaque composition comprising an orally acceptable vehicle and an effective antiplaque amount of at least one substantially water insoluble noncationic monohydroxy AA having one of the following formulae:

20


3



or



or III.



wherein R^1 is (1) a C1-8 n-alkyl, optionally partially or fully substituted with C3-6 cycloalkyls or C1-7 side chain alkyls, or (2) a C3-6 cycloalkyl, optionally partially or fully substituted with C1-7 side chain alkyls or C3-6 cycloalkyls;

the B ring and R^6 of formula I are interchangeably substituted in the 4 and 5 positions of the A ring of formula I, and R^6 is H or R^1 ; and

(1) R^2 and R^3 are interchangeably substituted in the 4' and 5' positions of the B ring of formula I, and 4 and 5 positions of formula II; R^2 is R^1 and R^3 is H or R^1 ; or

(2) in the B ring, R^3 in the 5'-position is H, R^2 in the 4' position is R^7 , R^7 is independently H or R^1 in the 2' and/or 3' positions, and n is 2;

R^4 in formula II is (1) t-butyl or C3-8 n-alkyl, optionally partially or fully substituted with C3-6 cycloalkyls or C1-7 side chain alkyls, or (2) C3-6 cycloalkyl optionally, partially or fully substituted with C1-7 side chain alkyls or C3-6 cycloalkyls; and

R^8 in formula III is independently H or R^1 in the 5, 6, 7 and/or 8 positions and m is 4.

We have further found that in the vast majority of instances, highly and unexpectedly superior antimicrobial activity is supplied by AA's of one of the above formulae containing t-butyl (tert-butyl) as at least one and preferably two (or even or more) of the R¹ and R⁴ values.

This invention is at least in part based on our further findings that:

1. tert-butyl (t-butyl) substitution at the ortho position of an unsubstituted phenol can enhance its antimicrobial effect by a factor of 10.


2. A second tert-butyl substitution at the 4 (para) position of an ortho tert-butyl substituted phenol (formula II) can enhance the antimicrobial effect of the resultant by an additional factor of 10.

3. tert-butyl substitution of the pendant phenyl group of a phenylphenol (formula I), e.g., substitution of 2-tert-butyl-5-phenyl phenol to give 2-tert-butyl-5-(4'-tert-butylphenyl) phenol likewise enhances the activity of the resultant by an additional factor of 10.


Thus, for instance, 3-phenyl phenol (3-hydroxybiphenyl) has an activity slightly less than that of thymol vs. *A. viscosus*, a common constituent of human dental plaque. On the other hand, 2-tert-butyl-5-phenyl phenol (3-hydroxy-4-tert-butylbiphenyl) has an observed activity 50 times greater than thymol and 2-tert-butyl-5-(4'-tert-butylphenyl)phenol (3-hydroxy-4,4'-di-tert-butylbiphenyl) has an observed activity greater than 100 times that of thymol.

As described herein other alkyl phenol AA's also provide enhanced antibacterial effectiveness for prevention or reduction of plaque formation.


By way of further example, phenols of the type



2-t-butyl-4-(4'-t-butylphenyl)phenol




2,4-di-t-butyl-5-methylphenol



2-t-butyl-4-(1,1,2,2-tetramethylpropyl)-5-methylphenol


(4) - (8)

2-t-butyl-4-R¹⁰-phenol

wherein

- (4) R¹⁰ = -C(CH₃)₃ (t-butyl)
- (5) R¹⁰ = phenyl
- (6) R¹⁰ = -C(CH₃)₂ CH₂ CH₃ (1, 1-dimethylpropyl)
- (7) R¹⁰ = -C(CH₃)₂ CH₂ CH₂ CH₃ (1,1-dimethylbutyl)
- (8) R¹⁰ = -C(CH₃)₂ C(CH₃)₃ (1,1,2,2-tetramethylpropyl)


and (9)




2-t-butyl-5-phenylphenol

can to have an activity level at least 10X that of thymol.


Phenols of the type:




2,4-di-t-butyl-5-phenylphenol



2-t-butyl-4-(1,1-dimethylpropyl)-5-phenylphenol



2-t-butyl-5-(4'-t-butyl-phenyl)phenol



2-t-butyl-3-hydroxy-10,10-dimethyl-9,10-dihydrophenanthrene

5

can have an activity level in the range 100X thymol. This is the activity level of triclosan.

The above AA compounds (1) - (13) fall within the scope of the AA agents of formulas I, II and III, and it will be understood that related compounds active as AA agents can be employed containing indicated variations in values, numbers and positions of R¹ - R⁴ and R⁶ - R⁸, as for example:

- 2-methyl -5-(4'-cyclopropylphenyl)phenol
- 2-octyl -5-(4'-cyclohexylphenyl)phenol
- 2-cyclohexyl -5-(4'-isopropylphenyl)phenol
- 10 2,4-diisopropyl-5-phenylphenol
- 2,4-dicyclopropyl-5-phenylphenol
- 2,4-dimethyl-5-phenylphenol
- 2-t-butyl-5(4'-isopropylphenyl)phenol
- 2-t-butyl-4(4'-cyclohexylphenyl)phenol
- 15 2-t-butyl-4-(1,1-dimethyloctyl)5-phenylphenol
- 2-(1-cyclopropylbutyl)-4-t-butyl-5-phenylphenol
- 2,4-diisohexylphenol
- 2,4-dicyclopropylphenol
- 2-isopropyl-4-phenylphenol
- 20 2-cyclobutyl-4-phenylphenol
- 2-ethyl-4-phenylphenol
- 2-isooctyl-5-phenylphenol
- 2-cyclopropyl-5-phenylphenol
- 2-methyl-5-phenylphenol
- 25 2-(1-t-butylhexyl)-5-phenylphenol
- 2,4-di-t-butyl-5-isopropylphenol
- 2-t-butyl-4-isopropyl-5-ethylphenol
- 2-isopropyl-4-t-butyl-5-butylphenol
- 2-(4'-t-butylcyclohexyl)4-methyl-5-amylphenol
- 30 2-(1,1-dimethylpropyl)-4-t-butylphenol
- 2-(1-cyclobutylhexyl)-4-octylphenol
- 2-t-butyl-3-hydroxy-10,10-di-t-butyl-9,10-dihydrophenanthrene
- 2-(1,1-dimethylpropyl-3-hydroxy-10,10-di-cyclohexyl-9,10-
- 35 dihydrophenanthrene

While 2-tert-butyl-5-phenyl phenol (3-hydroxy-4-tert-butylbiphenyl) is known, its use as an antimicrobial is not believed to have been reported in the literature. The same applies to a number of other compounds of any of the above formulae, for instance formulae I and II. As described below, a number of the AA's are also novel.

The improved antimicrobial activities attainable in accordance with this invention generally involves use of branched in preference to straight chains, selective positioning of substituents, increased numbers of substituents and/or the carbon content of alkyl substituents. The improved antimicrobial activities are unexpected, particularly in view of teachings to the contrary in the prior art. For example, C. M. Suter, Chem. Rev. 28 269-299(1941), in discussing phenol coefficients of alkylphenols v. *B. typhosus* and *Staph. aureus*, states (a) "the position of the alkyl group has no effect", and (b) "the o-and p-sec-butyl phenols have phenol coefficients of 28, and the branching of the carbon side chain, as in tert.butylphenol, reduces the effectiveness to about 20" (p. 272), and also (c) "the generalization that the straight-chain primary alkylphenols are more effective than their isomers" (p.273), "(d) It was concluded that the isobutyl compounds were probably less effective than their n-butyl isomers", and also (e) "As in the alkylphenols, branching of the carbon chain reduces the effectiveness" (p.275). The microorganisms employed in the above-quoted situations were not those generally encountered in the oral cavity.

Evans et al, J. Periodontol. 48, 156-162 (1977) in an article entitled "In Vitro Antiplaque Effects of Antiseptic Phenols" concludes that whereas "3,5,4'-tribromosalicylanilide was found to be effective against growth and plaque formation of *A. viscosus*, *A. naeslundii*, *S. mutans* and *S. sanguis*, Dibromosalicil was found effective against *A. viscosus*. The other phenols (hexylresorcinol, thymol, phenylphenol and zinc phenolsulfonate) did not inhibit in vitro growth or plaque formation".

It will be understood that in the above formulae I, II and III of the AA's employed in the oral compositions of this invention, the C₁₋₇ and C₁₋₈ side chain and n-alkyls range from methyl to heptyl and octyl and the C₃₋₆ cycloalkyls range from cyclopropyl to cyclohexyl. These AA's generally range in molecular weight (M.W.) from about 175 to about 500, preferably about 190 to about 350, more preferably about 210 to about 310. The AA is employed in the oral compositions of the invention in a non-toxic, effective antiplaque amount, typically in a range of about 0.003-5%, preferably about 0.005-3%, more preferably about 0.02-1%. The pH of the oral compositions of this invention may range from about 4.0 to about 9.0.

To increase substantivity and enhance the antibacterial activity of the AA even more, an antibacterial enhancing agent (AEA) may be included in the oral composition. The use of AEA's in combination with water-insoluble noncationic antibacterial compounds is known to the art, as for example U.S. Pat. No. 5,188,821 and 5,192,531. An AEA agent is an organic material which contains a delivery-enhancing group and a retention-enhancing group. As employed herein, the delivery-enhancing group refers to one which attaches or substantively, adhesively, cohesively or otherwise bonds the AEA agent (carrying the AA compound) to oral (e.g. tooth and gum) surfaces, thereby "delivering" the compound to such surfaces. The organic retention-enhancing group,, generally hydrophobic, attaches or otherwise bonds the AA to the AEA, thereby promoting retention of the AA to the AEA and indirectly on the oral surfaces. The enhanced retention of the AA on the oral surfaces results in an improvement in the retardatoin of plaque growth on oral surfaces.

Preferably, the AEA is an anionic polymer comprising a chain or backbone containing repeating units each preferably containing at least one carbon atom and preferably at least one directly or indirectly pendent, monovalent delivery-enhancing group and at least one directly or indirectly pendent monovalent retention-enhancing group geminally, vicinally or less preferably otherwise bonded to atoms, preferably carbon, in the chain.

The AEA may be a simple compound, preferably a polymerizable monomer, more preferably a polymer, including for example oligomers, homopolymers, copolymers of two or more monomers, ionomers, block copolymers, graft copolymers, cross-linked polymers and copolymers, and the like, The AEA may be natural or synthetic, and water insoluble or preferably water (saliva) soluble or swellable (hydratable, hydrogel forming) having an (weight) average molecular weight of about 100 to about 5,000,000, preferably about 1,000 to about 1,000,000, more preferably about 25,000 to 500,000.

In the case of the polymeric AEA's, it is desirable, for maximizing delivery and retention of the AA to oral surfaces, that the repeating units in the polymer chain or back-bone containing the acidic delivery enhancing groups constitute at least about 10%, preferably at least about 50%, more preferably at least about 80% up to 95% or 100% by weight of the polymer,

The AEA generally contains at least one delivery-enhancing group, which is preferably acidic such as sulfonic, phosphinic, or more preferably phosphonic or carboxylic, or a salt thereof, e.g. alkali metal or ammonium and at least one organic retention-enhancing group, such typically groups having the formula $-(X)_n-R$ wherein

5 X is O, N, S, SO, SO₂, P, PO or Si or the like, R is hydrophobic alkyl, alkenyl, acyl, aryl, alkaryl, aralkyl, heterocyclic or their inert-substituted derivatives, and n is zero or 1 or more. The aforesaid "inert-substituted derivatives", are intended to include substituents on R which are generally non-hydrophilic and do not significantly interfere with the desired function of the AEA as enhancing the delivery of the AA to

10 and retention thereof on oral surfaces such as halo, e.g. Cl, Br, I, and carbo and the like. Illustrations of such retention-enhancing groups are tabulated below.

-n	X	-(X) _n R
0	—	methyl, ethyl, propyl, butyl, isobutyl, t-butyl, cyclohexyl, allyl, benzyl, phenyl, chlorophenyl, xylyl, pyridyl, furanyl, acetyl, benzoyl, butyryl, terephthaloyl.
1	O	ethoxy, benzyloxy, thioacetoxy, phenoxy, carboethoxy, carbobenzyloxy.
	N	ethylamino, diethylamino, propylamido, benzylamino, benzoylamido, phenylacetamido.
	S	thiobutyl, thioisobutyl, thioallyl, thiobenzyl, thiophenyl, thiopropionyl, phenylthioacetyl, thiobenzoyl.
	SO	butylsulfoxy, allylsulfoxy, benzylsulfoxy, phenylsulfoxy.
	SO ₂	butylsulfonyl, allylsulfonyl, benzylsulfonyl, phenylsulfonyl.
	P	diethylphosphinyl, ethylvinylphosphinyl, ethylallylphosphinyl, ethylbenzylphosphinyl, ethylphenylphosphinyl.
	PO	diethylphosphinoxy, ethylvinylphosphinoxy, methylallylphosphinoxy, methylbenzylphosphinoxy, methylphenylphosphinoxy.
	Si	trimethylsilyl, dimethylbutylsilyl, dimethylbenzylsilyl, dimethylvinylsilyl, dimethylallylsilyl.

Preferably, the AEA is a natural or synthetic anionic polymeric polycarboxylate having a molecular weight of about 1,000 to about 5,000,000, preferably about 30,000 to about 500,000.

The synthetic anionic polymeric polycarboxylates are generally employed in the form of their free acids or preferably partially or more preferably fully neutralized water soluble alkali metal (e.g. potassium and preferably sodium) or ammonium salts. Preferred are 1:4 to 4:1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, preferably methyl vinyl

either/maleic anhydride having a molecular weight (M.W.) of about 30,000 to about 1,000,000, most preferably about 30,000 to about 500,000. These copolymers are available, for example, as Gantrez®, e.g. AN 139 (M.W. 500,000), AN 119 (M.W. 250,000); and preferably S-97 Pharmaceutical Grade (M.W. 70,000), of GAF Corporation.

Other polymeric polycarboxylates containing or modified to contain retention enhancing groups operative in the practice of the present invention include the 1:1 copolymers of maleic anhydride with ethyl acrylate, hydroxyethyl methacrylate, N-vinyl-2-pyrrolidone, or ethylene, the latter being available, for example, as Monsanto EMA® No: 1103, M.W. 10,000 and Grade 61, and 1:1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl methacrylate, isobutyl vinyl ether or N-vinyl-2-pyrrolidone.

Additional operative polymeric polycarboxylates containing or modified to contain retention enhancing groups include copolymers of maleic anhydride with styrene, isobutylene or ethyl vinyl ether, polyacrylic, polyitaconic and polymaleic acids, and sulfonacrylic oligomers of M.W. as low as 1,000 available as Uniroyal® ND-2.

Also suitable for use in the practice of the present invention are polymerized olefinically or ethylenically unsaturated carboxylic acids containing an activated carbon-to-carbon olefinic double bond which readily functions on polymerization because of its presence in the monomer molecule either in the alpha-beta position with respect to a carboxyl group or as part of a terminal methylene grouping. Illustrative of such acids are acrylic, methacrylic, ethacrylic, alpha-chloroacrylic, crotonic, beta-acryloxy propionic, sorbic, alpha-chlorosorbic, cinnamic, betastyrylacrylic, muconic, itaconic, citraconic, mesaconic, glutaconic, aconitic, alpha-phenylacrylic, 2-benzyl acrylic, 2-cyclohexylacrylic, angelic, umbellic, fumaric, maleic acids and anhydrides. Other different olefinic monomers copolymerizable with such carboxylic monomers include vinylacetate, vinyl chloride, dimethyl maleate and the like. Copolymers contain sufficient carboxylic salt groups for water-solubility.

Also useful in the practice of the present invention are so-called carboxyvinyl polymers. They are commercially available, for example, under the trademarks Carbopol® 934, 940 and 941 of B.F. Goodrich, these products consisting of a colloiddally water-soluble polymer of polyacrylic acid crosslinked with from about 0.75% to about

2.0% of polyallyl sucrose or polyallyl pentaerythritol as a cross linking agent, often with M.W.'s up to 4-5 million or more.

Illustrative of AEA's containing phosphinic acid and/or sulfonic acid delivery enhancing groups, are polymers and copolymers containing units or moieties derived from the polymerization of vinyl or allyl phosphinic and/or sulfonic acids substituted as needed on the 1 or 2 or 3 carbon atom by an organic retention-enhancing group, for example having the formula $-(X)_n-R$ defined above. Mixtures of these monomers may be employed, and copolymers thereof with one or more inert polymerizable ethylenically unsaturated monomers such as those described above with respect to the operative synthetic anionic polymeric polycarboxylates.

As an example of a polymer containing repeating units in which one or more phosphonic acid delivery-enhancing groups are bonded to one or more carbon atoms in the polymer chain is poly(vinyl phosphonic acid) containing units of the formula:



which may be an AEA even though it does not contain a retention-enhancing group. A group of the latter type would however be present in poly (1-phosphonopropene) with units of the formula:



A preferred phosphonic acid-containing polymer for use herein is poly (beta styrene phosphonic acid) containing units of the formula:



wherein Ph is phenyl, the phosphonic delivery-enhancing group and the phenyl retention-enhancing group being bonded on vicinal carbon atoms in the chain, or a copolymer of beta styrene phosphonic acid with vinyl phosphonyl chloride having the units of formula C alternating or in random association with units of formula I above, or poly(alpha styrene phosphonic acid) containing units of the formula:

D. $-\text{[CH}_2 - \text{C]}-$

/\

5 $\text{Ph PO}_3\text{H}_2$

in which the delivery - and retention-enhancing groups are terminally bonded to the chain.

10 These styrene phosphonic acid polymers and their copolymers with other inert ethylenically unsaturated monomers generally have molecular weights in the range of about 2,000 to about 30,000, preferably about 2,500 to about 10,000.

Other phosphonic-containing polymers include, for example, phosphonated ethylene having units of the formula:

15

E. $-(\text{CH}_2)_{14}\text{CHPO}_3\text{H}_2]_n-$

where n may for example be an integer or have a value giving the polymer a molecular weight of for example about 3,000; and sodium poly (butene-4,4-diphosphonate) having units of the formula:

20

$-(\text{CH}_2 - \text{CH}-)-$

\

$\text{CH}_2\text{CH} < (\text{PO}_3\text{Na}_2)_2$

25

and poly(allyl bis (phosphonoethyl) amine) having units of the formula:

F. $-(\text{CH}_2 - \text{CH}-)-$

\

$\text{CH}_2 - \text{N} < (-\text{C}_2\text{H}_4\text{PO}_3\text{H}_2)_2$

30

Other phosphonated polymers, for example poly (allyl phosphono acetate), phosphonated polymethacrylate, etc. and the geminal diphosphonate polymers disclosed in EP Publication 0321233 are also useful in the practice of the present invention preferably provided that they contain or are modified to contain the above-defined organic retention-enhancing groups.

Polysiloxanes containing or modified to contain pendant delivery-enhancing groups and retention enhancing groups such as liquid silicone oils such as diphenyl or

di (C₁-C₄) alkyl polysiloxanes and particularly dimethyl-polysiloxane, may also be employed in the practice of the present invention.

Also effective herein are ionomers containing or modified to contain delivery-
5 and-retention-enhancing groups. Ionomers are described on pages 546-573 of the Kirk
Othmer Encyclopedia of Chemical Technology, third edition, Supplement Volume,
John Wiley & Sons, Inc. copyright 1984, which description is incorporated herein by
reference. Also effective herein, provided they contain or are modified to contain
10 retention-enhancing groups, are polyesters, polyurethanes and synthetic and natural
polyamides including proteins and proteinaceous materials such as collagen, poly
(arginine) and other polymerized amino acids.

The AEA, when employed, is incorporated in the compositions of the present
15 invention in weight amounts of about 0.05 to about 5%, preferably about 0.1 to about
3%.

Linear molecularly dehydrated polyphosphate salts can be optionally
employed herein as anticalculus agents. They are well known, being generally
20 employed in the form of their wholly or partially neutralized water soluble alkali
metal (e.g. potassium or preferably sodium) or ammonium salts, and any mixtures
thereof. Representative examples include sodium hexametaphosphate, sodium
tripolyphosphate, monosodium triacid-, disodium diacid-, trisodium monoacid-, and
tetrasodium-pyrophosphates, the corresponding potassium salts and the like. In the
25 present invention, they can be employed in the oral compositions in approximate
weight amounts of about 0.1 to 3%, typically 1 to 2.5%, more typically 1.5 to 2%,
especially about 2%.

Particularly desirable anticalculus agents are tetraalkali metal pyrophosphates
30 such as tetrasodium and tetrapotassium pyrophosphates, and mixtures thereof.

In the oral compositions, when both AEA and polyphosphate are present, the
weight ratio of the AEA to polyphosphate ions is typically about 1.6:1 to about 2.7:1,
preferably about 1.7:1 to about 2.3:1, more preferably about 1.9:1 to about 2:1.

35 Fluoride ions may desirably also be included in the oral compositions of this
invention, being in effect multifunctional in providing an anticaries effect or tooth-
hardening effect and, in optional conjunction with the AEA, in inhibiting the salivary
enzymatic hydrolysis of the polyphosphate anticalculus agent, when employed.

An amount of a source of fluoride ions, or fluorine-providing component, may be included to provide or supply about 25 ppm to 5,000 ppm of fluoride ions.

5 These compounds may be slightly soluble in water or may be fully water-soluble. They are characterized by their ability to release fluoride ions in water and by substantial freedom from undesired reaction with other compounds of the oral composition. Among these materials are inorganic fluoride salts, such as soluble
10 alkali metal, alkaline earth metal salts, for example, sodium fluoride, potassium fluoride, ammonium fluoride, calcium fluoride, a cuprous fluoride, zinc fluoride, barium fluoride, sodium monofluorophosphate, aluminum mono- and di-fluorophosphate and sodium calcium fluorophosphate. Alkali metal and tin fluorides, such as sodium and stannous fluorides, sodium monofluorophosphate (MFP) and mixtures thereof, are preferred.

15 The amount of fluorine-providing compound is dependent to some extent upon the type of compound, its solubility, and the type of oral composition, but it must be a non-toxic amount, generally about 0.0005 to about 3.0% in the preparation. Any suitable minimum amount of such compound may be used, but it is preferable to
20 employ sufficient compound to release about 300 to 2,000 ppm, more preferably about 800 to about 1,500 ppm of fluoride ion.

25 Typically, in the cases of alkali metal fluorides, this component is present in an amount up to about 2% by weight, based on the weight of the composition, and preferably in the amount of about 0.05% to 1%, more typically about 0.2 to 0.35% for sodium fluoride. In the case of sodium monofluorophosphate, the compound may be present in an amount of about 0.1-3%, more typically about 0.76% by weight.

30 The oral composition of the present invention may be a solution of ingredients such as a mouthrinse or it maybe a semi-solid such as a toothpaste or gel dentifrice which may contain 0 to 75% of polishing agent, or chewing gum or solid lozenge or the like.

35 Oral gel preparations contain a siliceous polishing material including crystalline silica having particle sizes of up to about 5 microns, silica gel, colloidal silica or complex amorphous alkali metal aluminosilicate.

When visually clear or opacified gels are employed, a polishing agent of colloidal silica, such as those sold under the trademark Sylox® as Silox 15, or under the trademark Syloid® as Syloid 72 and Syloid 74, or under the trademark Santocel® as Santocel 100, or under the trademark Zeodent® as Zeodent 113 or alkali metal aluminosilicate complexes (that is, silica containing alumina combined in its matrix) are particularly useful, since they are consistent with gel-like texture and have refractive indices close to the refractive indices of gelling agent-liquid (including water and/or humectant) systems commonly used in dentifrices.

10 In the aspect of this invention wherein the oral composition is a gel or paste, an orally acceptable vehicle, including a water-phase with humectant which is preferably glycerine or sorbitol or an alkylene glycol such as polyethylene glycol or propylene glycol is present, wherein water is present typically in an amount of about 15-40% by weight and glycerine, sorbitol and/or the alkylene glycol (preferably propylene glycol) typically total about 20-75% by weight of the oral composition, more typically about 25-60%.

20 When the oral composition is substantially semi-solid or pasty in character, such as a toothpaste (dental cream), the vehicle of the dentifrice contains a dentally acceptable polishing material such as sodium bicarbonate or water insoluble polishing material such as sodium metaphosphate, potassium metaphosphate, tricalcium phosphate, dihydrated dicalcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, calcium carbonate, aluminum silicate, hydrated alumina, silica, bentonite, and mixtures thereof with each other or with minor amounts of hard 25 polishing materials such as calcined alumina and zirconium silicate. Preferred polishing materials include silica, insoluble sodium metaphosphate, dicalcium phosphate, calcium pyrophosphate and hydrated alumina, as well as sodium bicarbonate.

30 The polishing material is generally present in the gel, cream or paste compositions in weight concentrations of about 10% to about 75% by weight, preferably about 10% to about 30% in a gel and about 25% to about 75% in a cream or paste.

35 Toothpastes or dental cream dentifrices as well as gel dentifrices typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10%, preferably about 0.5 to about 5%.

Suitable thickeners or gelling agents include Irish moss, iota-carrageenan, kappa-carrageenan, gum tragacanth, starch, polyvinylpyrrolidone, hydroxyethyl propyl cellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose and sodium carboxymethyl cellulose.

5

In the aspect of the present invention wherein the oral composition is substantially liquid in character such as a mouthwash or rinse, the vehicle is typically a water-alcohol mixture. Generally, the weight ratio of water to alcohol is in the range of from about 3:1 to 10:1 and preferably about 4:1 to about 6:1. The alcohol is a non-toxic alcohol such as ethanol or isopropanol. A humectant such as glycerine, sorbitol or an alkylene glycol such as polyethylene glycol or preferably propylene glycol may be present in amount of about 10-30% by weight. Mouthrinses typically contain about 50-85% of water, about 0 to 20% by weight of a non-toxic alcohol and about 10-40% by weight of the humectant.

15

Organic surface-active agents are used in the compositions of the present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion of the AA throughout the oral cavity, and render the instant compositions more cosmetically acceptable. The organic surface-active material is preferably anionic, nonionic or ampholytic in nature, and it is preferred to employ as the surface-active agent a detergent material which imparts to the composition detergent and foaming properties. Suitable examples of anionic surfactants are water-soluble salts of higher fatty acid monoglyceride monosulfates, such as the sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene sulfonate, higher alkyl sulfoacetates, higher fatty acid esters of 1,2-dihydroxy propane sulfonate, and the substantially saturated higher aliphatic acyl amides of lower aliphatic amino carboxylic acid compounds, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals and alkoyl taurines, and the like. Examples of the last mentioned amides and taurates are N-lauroyl sarcosine, and the sodium, potassium and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from soap or similar higher fatty acid material as well as N-methyl-N-cocoyl (or oleoyl or palmitoyl) taurines. The use of these sarcosinate compounds in the oral compositions of the present invention is often advantageous since these materials exhibit a prolonged and marked effect in the inhibition of acid formation in the oral cavity due to carbohydrate breakdown in addition to exerting some reduction in the solubility of tooth enamel in acid solutions.

35

5 Examples of water-soluble nonionic surfactants are condensation products of ethylene oxide with various reactive hydrogen-containing compounds reactive therewith having long hydrophobic chains (e.g. aliphatic chains of about 12 to 20 carbon atoms), which condensation products ("ethoxamers") contain hydrophilic polyoxyethylene moieties, such as condensation products of poly (ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols (e.g. sorbitan monostearate) and polypropyleneoxide (e.g. Pluronic® materials).

10 Examples of polyoxamers useful in the practice of the present invention include block copolymers of polyoxyethylene and polyoxypropylene having an average molecular weight from about 3000 to 5000 and a preferred average molecular weight from about 3500 to about 4000 and containing about 10-80% hydrophilic polyoxyethylene groups, by weight, of the block copolymer. A preferred polyoxamer useful in the practice of the present invention is Pluronic F127 (trademark) a block
15 copolymer of polyoxyethylene and polyoxypropylene having a molecular weight of about 4000.

Any suitable flavoring or sweetening material may also be employed. Examples of suitable flavoring constituents are flavoring oils, e.g. oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, cinnamon, lemon, and
20 orange, and methyl salicylate. Suitable sweetening agents include sucrose, lactose, maltose, xylitol, sodium cyclamate, perillartine, aspartyl phenyl alanine methyl ester, saccharine and the like. Suitably, flavor and sweetening agents may each or together comprise from about 0.1% to 5% or more of the preparation.

25 Agents used to diminish teeth sensitivity such as strontium chloride, potassium nitrate and potassium citrate can also be included in the oral compositions of the present invention at concentrations of about 0.1 about 10% by weight.

30 Various other materials may be incorporated in the oral compositions of this invention including whitening agents such as urea peroxide and hydrogen peroxide, preservatives, such as sodium benzoate, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof. These
35 adjuvants, when present, are incorporated in the compositions in amounts which do not substantially adversely affect the properties and characteristics desired.

The oral compositions of the present invention may be prepared by suitably mixing the ingredients. For instance, in the preparation of a mouthrinse, the AA is

dispersed in a mixture of ingredients, e.g. alcohol, humectants, surfactants, and AEA and salts such as sodium fluoride and potassium phosphate, and flavor are then added and mixed. The ingredients are then mixed under vacuum for about 15-30 minutes. The resulting rinse is then packaged. Dentifrices are prepared similarly, the additional thickener and polishing agents being included in the last or penultimate step.

In the preferred practice of this invention an oral composition according to this invention such as a dentifrice is preferably applied as by brushing regularly to dental enamel, such as every second or third day or preferably from 1 to 3 times daily, at a pH of about 4.5 to 10, generally about 5.5 to 9, preferably about 6 to 8, for at least 2 weeks up to 8 weeks or more up to lifetime. The dentifrice is typically removed by rinsing with water after each application. Mouthrinses are rinsed or gargled in similar systematic manner

The compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g. by stirring into a warm gum base or coating the outer surface of a gum base, illustrative of which may be mentioned jelutone, rubber latex, vinylite resins, etc., desirably with conventional plasticizers or softeners, sugar or other sweeteners or carbohydrates such as glucose, sorbitol and the like.

The vehicle or carrier in a tablet or lozenge is a non-cariogenic solid water-soluble polyhydric alcohol (polyol) such as mannitol, xylitol, sorbitol, malitol, a hydrogenated starch hydrolysate, Lycasin, hydrogenated glucose, hydrogenated disaccharides or hydrogenated polysaccharides, in an amount of about 90 to 98% by weight of the total composition. Solid salts such as sodium bicarbonate, sodium chloride, potassium bicarbonate or potassium chloride may totally or partially replace the polyol carrier.

Tableting lubricants, in minor amounts of about 0.1 to 5% by weight, may be incorporated into the tablet or lozenge formulation to facilitate the preparation of both the tablets and lozenges. Suitable lubricants include vegetable oils such as coconut oil, magnesium stearate, aluminum stearate, talc, starch and Carbowax®.

Lozenge formulations contain about 2% gum as a barrier agent to provide a shiny surface as opposed to a tablet which has a smooth finish. Suitable non-cariogenic gums include kappa carrageenan, carboxymethyl cellulose, hydroxyethyl cellulose, Gantrez®, and the like.

5 The lozenge or tablet may optionally be coated with a coating material such as waxes, shellac, carboxymethyl cellulose, polyethylene/maleic anhydride copolymer or kappa-carrageenan to further increase the time it takes the tablet or lozenge to dissolve in the mouth. The uncoated tablet or lozenge is slow dissolving, providing a sustained release rate of active ingredients of about 3 to 5 minutes. Accordingly, the solid dose tablet and lozenge composition of this invention affords a relatively longer time period of contact of the teeth in the oral cavity with the active ingredients.


10 In Table I below following illustrative Example 9, categories of AA's are listed. Category I sets forth AA's which are indicated to be 100 or more times more active than thymol. That is, they would be comparable to or even more effective than triclosan in antiplaque activity. Category II sets forth AA's which are lower in activity, e.g. 10 to 50 times than the activity of thymol.

15

A further aspect of this invention relates to compounds of this Category I which are characterized as having one of the following formulae:


23

III.



or

IV.



wherein R^1 is (1) a C₁-8 n-alkyl, partially or fully substituted with C₃-6 cycloalkyls or C₁-7 side chain alkyls or (2) a C₃-6 cycloalkyl, optionally partially or fully substituted with C₁-7 side chain alkyls or C₃-6 cycloalkyls;

and

each R^3 is independently hydrogen or R^1 , with the proviso that when R^3 in the A ring of formula IV is hydrogen at least one R^3 in the B ring is R^1 .

A preferred compound of formula III is 2-t-butyl-3-hydroxy-10,10-dimethyl-9,10-dihydrophenanthrene. Preferred compounds of formula IV are:

2-t-butyl-5-(4'-t-butylphenyl)phenol;

2,4-di-t-butyl-5-phenyl phenol; and

2-t-butyl-4-(1,1-dimethylpropyl)-5-phenyl phenol

General Synthetic Procedure for the Alkylated Phenol
Antibacterial Agents Employed Herein

5 The AA's of this invention, some of which may be found in nature, are made synthetically by Friedel-Crafts alkylation in accordance with typical methods of synthetic organic chemistry. Thus, a phenolic compound, e. g. phenol, 3-phenylphenol, 4-phenylphenol, or 9,10-dihydro-3-hydroxy-10,10-dimethylphenanthrene, is treated with RX, where R is an alkyl moiety and X is halide
10 or other appropriate leaving group, in the presence of a suitable Friedel-Crafts catalyst, e. g. aluminum chloride or ferric chloride, either neat or in a suitable solvent, e. g. methylene chloride, carbon disulfide, or nitrobenzene. Treatment of a phenolic compound with one equivalent of RX results in predominantly mono alkyl substitution *ortho* to the phenol hydroxyl. Treatment of a phenolic compound with
15 two or more equivalents of RX results in di- or polyalkyl- phenols. Multiple alkylation can also be done stepwise. Unsymmetrically substituted polyalkylphenols may be obtained by starting with a 3-alkylphenol. It is noteworthy that in dialkylating biphenylphenols with bulky alkyls, e. g. *t*-butyl, the first alkyl is introduced *ortho* to the hydroxyl while the second alkyl substitution occurs on the pendant phenyl. These
20 methods are illustrated by the syntheses of 2-*tert*-butyl-5-phenylphenol and 2-*tert*-butyl-5-(4-*tert*-butylphenyl)phenol, shown below as Examples 1 and 2, respectively.

 In order to obtain 2,4-di-*tert*-butyl-5-phenylphenol, 3-nitrophenylphenol is alkylated with two moles of *t*-butyl chloride according to the method described above.
25 The nitro group of the resulting 2,4-di-*tert*-butyl-5-nitrophenylphenol is removed by catalytic hydrogenation, followed by diazotization and reduction of the diazonium salt of the aniline*.

30 * See N. Porowska, W. Polackowa, and S. Kwiatkowska, *Rocz. Chem.*, 44 (2), 375 (1970).

Ortho, *meta*, and *para* mono *n*-alkyl substituted phenols are preferably obtained, as follows. The alkyl halide R'X, where R' is one methylene group shorter than the desired alkyl chain R, is reacted with magnesium to form the corresponding Grignard
35 R'MgX. This is reacted with *o*-, *m*-, or *p*-anisaldehyde to yield a 2-hydroxyalkyl anisole. The hydroxy group is removed by hydrogenolysis over palladium on carbon in refluxing cyclohexene to give the *n*-alkyl substituted anisole. The desired *n*-alkyl

substituted phenol is generated by cleavage of the methyl group from the anisole by treatment with boron tribromide^o.

^o J. Weinstock, *et. al.*, J. Med. Chem., 30, 1166 (1987).

5

Similar alkylation can be accomplished by substitution of RX in the foregoing description with an appropriate olefin.

10 The SIKT (Short Interval Kill Test) test referred to in the examples is used to assess the ability of actives to kill in a short period of time (e.g. 2 minutes), simulating antiplaque mouthrinse conditions. In this test, which is described in U.S. Patent No. 5,275,805, column 11, lines 10-28, which description is herewith incorporated herein, control and test samples are mixed with pre-determined inoculums of *S. sanguis*,
15 *S. mutans* and *S. viscosus* (10^6 - 10^7 Colony forming unit (cfu/ml.) for 2 minute contact times, the systems then neutralized to inhibit further antibacterial activity, and the surviving bacteria enumerated using plate count methodology. The reduction in cfu counts compared to the water control is the basis for expressing the antibacterial activity of the test agents, i.e. as % killing in comparison to the appropriate placebo or
20 control.

 The MIC (Minimum Inhibitory Concentration) test referred to in the examples measures the minimum concentration in ppm or mM of the AA at which the growth of the bacteria (same 3 plaque involved species as employed in the SIKT tests) is
25 completely inhibited by the AA. The smaller the MIC, the greater the antibacterial activity of the AA being tested. This MIC test is also described in U.S. Patent No. 5,275,805 at column 11, lines 54-68, which description is herewith incorporated herein.

 The following examples are further illustrative of the nature of the present
30 invention, but it is understood that the invention is not limited thereto. All amounts and proportions referred to herein and in the appended claims are by weight unless otherwise indicated.

35

Example 12-tert-butyl-5-phenylphenol (3-hydroxy-4-butyl-biphenyl)

5

A suspension of 0.8 aluminum chloride in 50 mL of anhydrous methylene chloride is stirred under an anhydrous nitrogen atmosphere at 5-15°C while a solution of 17g of 3-phenylphenol and 24 mL of t-butylchloride in 50 mL of anhydrous methylene chloride is added dropwise. The resultant mixture is stirred for 2 hours, then allowed to stand at room temperature for 12 hours. The reaction mixture is poured over 150g of ice/water and shaken. The organic phase is separated and the aqueous remainder is twice extracted with 50 mL portions of methylene chloride. The combined organic solutions are washed twice with 50 mL portions of water, 50 mL of saturated aqueous sodium chloride solution, rendered anhydrous over sodium sulfate, filtered, and evaporated *in vacuo*. The residue is taken into about 150 mL of hexane. Upon standing at room temperature, 3-hydroxy-4-t-butylbiphenyl crystallizes from the solution. This is isolated by filtration and successively recrystallized from 100 mL portions of pentane until its melting point becomes constant. The material is obtained as a white crystalline compound in 6.8g yield, m.p. 86-87°C. The original hexane filtrates also produce another crop of crystals which provides 1.1g of 2-tert-butyl-5-(4'-tert-butylphenyl) phenol, m.p. 143-145°C after several recrystallizations from pentane. An additional 1.12g of this material are obtained from the chromatography of the mother liquor residues.

10

15

20

Example 22-tert-butyl-5-(4'-tert-butylphenyl)phenol

- 5 A mixture of 25g of 3-phenylphenol (3PP) in 100 mL t-butyl chloride is stirred under an anhydrous nitrogen atmosphere and heated briefly. The mixture is allowed to cool somewhat, and a 1.0g portion of anhydrous aluminum chloride is added, all at once. After 1.5 hours, a 15 mL portion of t-butyl chloride is added, followed by 0.8 g of aluminum chloride. The mixture is stirred 45 minutes at reflux, then a 200 mL
- 10 portion of chloroform is added. The solution is poured into 200 mL of water and the mixture is shaken. The organic layer is separated and the aqueous layer was extracted with 100 mL of chloroform. The combined organic layers (300 mL) are washed successively with 100 mL portions, each of 6N hydrochloric acid (2X), water, aq. 5% sodium bicarbonate, water, and saturated aqueous sodium chloride solution. The
- 15 organic solution is rendered anhydrous over sodium sulfate, filtered, and evaporated *in vacuo*. The residue is taken into 150 mL of boiling hexane. The solution is chilled until product crystallization is complete. The mixture is filtered and the crude product washed with cold hexane and allowed to air dry to yield 29g. white solid. The crude product is recrystallized again from hexane to give 22.3g. analytically pure
- 20 2-tert-butyl-5-(4'-tert-butylphenyl)phenol as a white crystalline solid, mp. 145-147°C. Elemental Analysis: Calc.; C, 85.06%, H, 9.28%, Found; C, 84.74%, H, 9.55%. Infrared, carbon and proton NMR support the assigned structure.

EXAMPLES 3 & 4

25

Liquid Dentifrice Composition	Placebo (g.)	Example 3 (g.)	Example 4 (g.)
Ingredients			
Glycerol (99.7% stock)	20.000	20.000	20.000
Sorbitol (70% stock)	20.000	20.000	20.000
Propylene glycol	0.500	0.500	0.500
Sodium lauryl sulfate	1.500	1.500	1.500
Gantarez (13.2% stock) S97	15.150	15.150	15.150
Triclosan			0.300
2,4-di-t-butyl phenol		0.300	
Sodium fluoride	0.243	0.243	0.243
Water	18.300	18.000	18.000
Flavor	1.000	1.000	1.000
pH 7.00			

MIC Liquid Dentifrice Test Results

	Bacterial species (MIC in ppm)		
	A. viscosus	S. sanguis	S. mutans
Placebo	7.80	7.80	3.90
Triclosan (Example 4)	3.90	3.90	3.90
2,4-di-t-butylphenol (Example 3)	7.80	3.90	3.90

5 In this MIC test the Example 3 formulation of this invention exhibits antibacterial activity equal to the triclosan Example 4 formulation v. *S. sanguis* and *S. mutans* and double that of the placebo v. *S. sanguis*.

SIKT Liquid Dentifrice Results

	SIKT (% killing)
Triclosan (Example 4)	92
2,4-di-t-butylphenol (Example 3)	80

10 In the control (water), the amount of bacteria present is 10^4 cells/ml. In comparison 10-15 cells are considered to be 100% kill. These SIKT tests show the antibacterial activity of the Example 3 formulation of this invention to achieve 100% kill and to be substantially like the triclosan Example 4 formulation.

EXAMPLE 5

Mouth formulation containing 3-hydroxy-4,4' -di-t-butyl biphenyl
(2-t. butyl-5(4'-t.butylphenyl)phenol)

5

Ingredients	%
Sorbitol (70%)	10.00
Glycerin (99.7%)	10.00
Ethanol (95%)	15.00
Propylene glycol	15.00
Sodium lauryl sulfate	0.50
Tauranol (97%)*	0.25
Pluronic F127**	0.25
Mint flavor	0.10
3-hydroxy-4,4' -di-t-butyl biphenyl	0.30
Water	48.60
Total	100.00

* Sodium methyl cocoyl taurate, trademark.

** Block copolymer polyoxypropylene/polyoxyethylene, M.W. 4000, trademark.

EXAMPLE 6

Toothpaste formulation containing 3-hydroxy-4,4'-di-t-butyl biphenyl

Ingredients	%
3-hydroxy-4,4'-di-t-butyl biphenyl	0.30
Sodium monofluorophosphate	0.19
Propylene glycol	30.00
Glycerin (99.7%)	10.00
Zeodent 115*	20.00
Sorbitol (70%)	25.00
Water	7.61
Sylodent 15**	2.00
Sodium lauryl sulfate	0.50
Pluronic F127	0.50
Tauranol (97%)	0.50
Flavor	1.00
K ₂ HPO ₄	0.50
Sodium carboxymethyl cellulose	0.80
Titanium dioxide	0.50
Iota-carrageenan***	0.30
Sodium saccharin	0.30
Total	100.00

5

- * Silica polishing agent, trademark.
- ** Silica thickener, trademark.
- *** Thickener, stabilizer.

10

The above formulation can be modified by replacing some or all Zeodent 115 silica polishing agent and Sylodent 15 silica thickener with sodium bicarbonate, insoluble sodium metaphosphate, dicalcium phosphate, calcium pyrophosphate, hydrated alumina and mixtures thereof.

In the following Examples 7, 8 and 9 the tests are carried out in neat solutions of the AA active agent in 98.5% ethanol (EtOH) which, at the test concentrations, does not show any antibacterial properties.

5 EXAMPLE 7

Minimum Inhibitory Concentration (MIC) Results

	Bacterial species (MIC in ppm)		
	A. viscosus	S. sanguis	S. mutans
2,4-di-t-butylphenol	1.95	1.95	0.98
Thymol	15.60	15.60	31.25
Triclosan	0.50	0.98	1.95

10 In this test, the 2,4-di-t-butyl phenol is found to be many times superior to thymol, significantly superior to triclosan against S. mutans and somewhat less active than triclosan against A. viscosus and S. sanguis.

EXAMPLE 8

15 2-tert-butyl-5-phenyl phenol and 2-tert-butyl-5-(4'-tert-butylphenyl) phenol are tested in vitro against several strains of bacteria typically found in human dental plaque. Experimental results are given below

Minimum Inhibitory Concentration (MIC) Results

	Bacterial species (MIC in ppm)		
	A. viscosus	S. sanguis	S. mutans
(1) 2-t-butyl-5-(4'-t-butylphenyl)phenol	0.061	0.0305	0.122
(2) 2-t-butyl-5-phenylphenol	0.976	0.976	0.976
Thymol	31.25	62.5	31.25
Triclosan	0.976	1.95	1.92

20 This test shows agent (1) to be substantially more active than any of the other agents, and agent (2) to be significantly more active than triclosan against S. sanguis and S. mutans and many times superior to thymol against all three strains.

EXAMPLE 9

SIKT test results (neat solutions of 3-hydroxy-4,4'-di-t-butyl biphenyl = 2-t-butyl-5 (4'-t-butylphenyl)phenol) against *A. viscosus*.

5

Agent	% killing vs. placebo
0.03% Triclosan	21.0
0.03% 3-hydroxy-4,4' di-t-butylbiphenyl	58.5

Each AA compound is formulated in 98.5% EtOH. At the concentrations present in the final test solutions the EtOH does not show any antibacterial properties by itself. The placebo is a formulation that contains no active agents, e.g., only EtOH. These tests show applicants' AA to have more than twice the antibacterial activity of triclosan against *A. viscosus*.

10

The following Table I lists preferred AA's of this invention in two categories. Predicted MIC's in mM are indicated as well as found values for several of them. In addition, MIC's of thymol and triclosan are set forth.

15

Predicted values are based on our above-referred to findings and other criteria including consideration of types, sizes, numbers and positions of substituents, their structure (straight, branched, cyclic alkyl), etc. Listed in Category I are novel compounds within the scope of formulas III and IV above, having predicted antibacterial activities 100X thymol and MIC's below about 0.4 mM. Listed in Category II are compounds, some of which are known, having predicted activities 10-50 X thymol and MIC's above about 0.04 mM. Experimental ("Found") MIC's of one AA in Category I and two in Category II support relatively conservatively predicted values in being substantially equal to or substantially lower (e.g. 0.0022 vs. 0.038 in Category I and 0.043 vs. 0.12 in Category II) and hence even substantially more antimicrobial against *A. viscosus* than predicted. The Table also shows that all listed AA's have substantially lower predicted and found MIC's than thymol, that the found MIC of category II AA compound 2-t-butyl-4-(4'-t-butylphenyl)phenol is about one-tenth that of triclosan, and that the predicted MIC's of 2,4-di-t-butyl-5-phenylphenol and 2-t-butyl-4-(1,1-dimethylpropyl)-5-phenylphenol are even lower than that of the 2-t-butyl-4-(4-t-butylphenyl)phenol and comparable to the MIC of triclosan.

20

25

30


TABLE IPhenol

		<u>MIC (mM) v A. viscosus</u>	
		<u>Predicted</u>	<u>Found</u>
Thymol		1.7	2.0
Triclosan		—	0.02
<u>Category I (Predicted 100X thymol)</u>			
2-t-butyl-5-(4'-t-butylphenyl)		0.038	0.0022
2,4-di-t-butyl-5-phenyl		0.025	
2-t-butyl-4-(1,1-dimethylpropyl)-5-phenyl		0.031	
2-t-butyl-3-hydroxy-10,10-dimethyl-9,10-dihydrophenanthrene		0.038	
<u>Category II (Predicted 10-50X thymol)</u>			
2,4-di-t-butyl		0.19	0.20
2-t-butyl-4-(4'-t-butylphenyl)		0.16	
2-t-butyl-4-phenyl		0.12	
2-t-butyl-5-phenyl		0.12	0.043
2,4-di-t-butyl-5-methyl		0.17	
2-t-butyl-4-(1,1-dimethylpropyl)		0.099	
2-t-butyl-4-(1,1-dimethylbutyl)		0.098	
2-t-butyl-4-(1,1,2,2-tetramethylpropyl)		0.11	
2-t-butyl-4-(1,1,2,2-tetramethylpropyl)-5-methyl		0.10	

5 This invention has been disclosed with respect to preferred embodiments thereof and it will be understood that variations and modifications obvious to those skilled in the art are intended to be included within the purview of this application and the scope of the appended claims.


CLAIMS

1. An oral composition comprising an orally acceptable vehicle and an effective antiplaque amount of at least one substantially water insoluble noncationic
 5 antibacterial agent (AA) of the formula:




or

II.



or

III.



- wherein R^1 is (1) a C₁₋₈ n-alkyl, optionally partially or fully substituted with C₃₋₆ cycloalkyls or C₁₋₇ side chain alkyls, or (2) a C₃₋₆ cycloalkyl, optionally partially or fully substituted with C₁₋₇ side chain alkyls or C₃₋₆ cycloalkyls;
- 5 the B ring and R^6 of formula I are interchangeably substituted in the 4 and 5 positions of the A ring of formula I, and R^6 is H or R^1 ; and
- (1) R^2 and R^3 are interchangeably substituted in the 4' and 5' positions of the B ring of formula I, and 4 and 5 positions of formula II, R^2 is R^1 and R^3 is H or R^1 ; or
- (2) in the B ring, R^3 in the 5'-position is H, R^2 in 4' position is R^7 , R^7 is independently
- 10 H or R^1 in the 2' and/or 3' positions, and n is 2;
- R^4 in formula II is (1) t-butyl or C₃₋₈ n-alkyl, optionally partially or fully substituted with C₃₋₆ cycloalkyls or C₁₋₇ side chain alkyls, or (2) C₃₋₆ cycloalkyl optionally, partially or fully substituted with C₁₋₇ side chain alkyls or C₃₋₆ cycloalkyls; and
- R^8 in formula III is independently H or R^1 in the 5, 6, 7 and/or 8 positions and m is 4.
- 15
2. A composition according to Claim 1 wherein the AA has formula II wherein R^4 is t-butyl.
3. A composition according to Claim 2 wherein one of R^2 and R^3 is
- 20 t-butyl and the other is H.
4. A composition according to Claim 3 wherein the AA comprises 2,4-di-t-butyl phenol.
- 25 5. A composition according to Claim 2 wherein the AA comprises 2,4-di-t-butyl-5-methyl phenol.
6. A composition according to Claim 2 wherein the AA comprises
- 30 2-t butyl-4- (1,1-dimethylpropyl)-phenol, 2-t-butyl-4- (1,1-dimethylbutyl)-phenol, 2-t-butyl-4- (1,1,2,2-tetramethylpropyl)-phenol, or 2-t-butyl-4-(1,1,2,2-tetramethylpropyl)-5-methyl-phenol.

7. A composition according to Claim 1 wherein the AA has formula I wherein R^1 is t-butyl.
- 5 8. A composition according to Claim 7 wherein one of R^2 and R^3 has an R^1 value and the other is H.
9. A composition according to Claim 8 wherein the AA comprises 2-t-butyl-5-phenyl phenol.
- 10 10. A composition according to Claim 8 wherein the AA comprises 2-t-butyl-4-phenyl phenol.
11. A composition according to Claim 8 wherein the AA comprises 2-t-butyl-5-(4'-t-butyl phenyl) phenol.
- 15 12. A composition according to Claim 8 wherein the AA comprises 2-t-butyl-4-(4'-t-butyl phenyl) phenol.
13. A composition according to Claim 8 wherein the AA comprises 2,4-di-t-butyl-5-phenyl phenol.
- 20 14. A composition according to Claim 8 wherein the AA comprises 2-t-butyl-4-(1,1-dimethylpropyl)-5-phenyl phenol.
- 25 15. A composition according to Claim 1 wherein the AA has formula III and R^1 in the 2-position is t-butyl.
16. A composition according to Claim 15 wherein the R^1 's in the 10-position are lower C1-6 alkyl.
- 30


17. A composition according to Claim 16 wherein the AA comprises 2-t-butyl-3-hydroxy-10,10-dimethyl-9,10-dihydrophenanthrene.
- 5 18. A composition according to Claim 1 wherein R^1 and R^4 in ortho position to the OH group, and R^2 in the 4' position in the B ring of formula I, are t-butyl.
- 10 19. A composition according to Claim 1 further containing about 0.05-5% of antibacterial-enhancing agent (AEA).
20. A composition according to Claim 19 wherein said AEA has an average molecular weight (M.W.) of about 100 to about 5,000,000.
- 15 21. A composition according to Claim 20 wherein said AEA contains at least one acidic delivery-enhancing group and at least one organic retention-enhancing group.
- 20 22. A composition according to Claim 21 wherein said delivery-enhancing group comprises carboxylic, phosphonic, phosphinic and/or sulfonic acid groups and salts and any mixtures thereof, and said organic retention-enhancing group has the formula-(X)_n-R wherein X is O, N, S, SO, SO₂, P, PO or Si, R is hydrophobic alkyl, alkylene, acyl, aryl, alkaryl, aralkyl, heterocyclic, or their inert-substituted derivatives, and n is 1 or zero.
- 25 23. A composition according to Claim 22 wherein said AEA is an anionic polymer containing a plurality of said delivery-enhancing and retention-enhancing groups.
- 30 24. A composition according to Claim 23 wherein said delivery-enhancing group comprises carboxylic or salt thereof.
25. A composition according to Claim 24 wherein said AEA is a copolymer of maleic acid or anhydride with another ethylenically unsaturated polymerizable monomer.

26. A composition according to Claim 25 wherein said other monomer is methyl vinyl either in a 4:1 to 1:4 molar ratio with the maleic acid or anhydride, and said copolymer has an average M.W. of about 70,000 to 250,000 and comprises about .05-3% of the composition.
27. A composition according to Claim 23 wherein said delivery-enhancing group comprises phosphonic or salt thereof.
28. A composition according to Claim 27 wherein said AEA comprises poly (beta-styrenephosphonic acid) or poly (alpha-styrenephosphonic acid) or a copolymer of either styrenephosphonic acid with another ethylenically unsaturated monomer.
29. A composition according to Claim 1 further containing an effective anticalculus amount of at least one linear molecularly dehydrated polyphosphate anticalculus agent.
30. A composition according to Claim 29 containing about 0.1 to 3% of said polyphosphate and the weight ratio of said AEA to polyphosphate ion ranges from about 1.6:1 to about 2.7:1.
31. A composition according to Claim 30 wherein said polyphosphate comprises tetrasodium or tetrapotassium pyrophosphate or a mixture thereof.
32. A composition according to Claim 19 further containing an effective anticalculus amount of at least one linear molecularly dehydrated polyphosphate anticalculus agent.

- 5 33. A composition according to Claim 22 further containing an effective anticalculus amount of at least one linear molecularly dehydrated polyphosphate anticalculus agent.
34. A composition according to Claim 1 further containing about 25-5,000 ppm of fluoride ions.
- 10 35. A composition according to Claim 19 further containing about 25-5,000 ppm of fluoride ions.
36. A composition according to Claim 32 further containing about 25-5,000 ppm of fluoride ions.
- 15 37. A composition according to Claim 1 wherein the AA has a molecular weight of about 175 to about 500.
38. A composition according to Claim 1 wherein the AA has a molecular weight of about 210 to about 310.
- 20 39. A composition according to Claim 1 wherein said composition contains about 10% to about 75% by weight of a dentally acceptable polishing agent.
40. A composition according to Claim 39 wherein said polishing agent is silica.
- 25 41. A method for inhibiting dental plaque comprising applying to the teeth plaque-inhibiting amount of an oral composition as defined in any one of Claims 1-40.


42. A compound characterized as having one of the following formulae:

III.



or

IV.



5

wherein R^1 is (1) a C₁-8 n-alkyl, partially or fully substituted with C₃-6 cycloalkyls or C₁-7 side chain alkyls or (2) a C₃-6 cycloalkyl, optionally partially or fully substituted with C₁-7 side chain alkyls or C₃-6 cycloalkyls;
and

- 10 each R^3 is independently hydrogen or R^1 , with the proviso that when R^3 in the A ring of formula IV is hydrogen at least one R^3 in the B ring is R^1 .

43. A compound according to claim 45 of formula IV.
44. A compound according to claim 46 wherein R¹ is t-butyl.
- 5 45. A compound according to claim 47 wherein said compound is 2-t-butyl-5-(4'-t-butylphenyl)phenol.
46. A compound according to claim 47 wherein said compound is 2,4-di-t-butyl-5-phenyl phenol.
- 10 47. A compound according to claim 47 wherein said compound is 2-t-butyl-4-(1,1-dimethylpropyl)-5-phenylphenol.
48. A compound according to claim 45 of formula III.
- 15 49. A compound according to claim 51 wherein R¹ in the 2 position is t-butyl.
50. A compound according to claim 52 wherein said compound is 2-t-butyl-3-hydroxy-10,10-dimethyl-9,10-dihydrophenanthrene.



11



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 7/16, C07C 39/06, 39/12, 39/17	A3	(11) International Publication Number: WO 97/10800 (43) International Publication Date: 27 March 1997 (27.03.97)
(21) International Application Number: PCT/US96/15017 (22) International Filing Date: 18 September 1996 (18.09.96) (30) Priority Data: 60/004,196 22 September 1995 (22.09.95) US (71) Applicant: COLGATE-PALMOLIVE COMPANY [US/US]: 300 Park Avenue, New York, NY 10022 (US). (72) Inventors: STRINGER, Orum, D.; 1109 Gloria Lane, Yardley, PA 19067 (US). BRAHMS, John, C.; Apartment B2, 222 Sullivan Way, Trenton, NJ 08628 (US). SUBRAMANIAN, Malathy; 20 Champions Circle, Branchburg, NJ 08876 (US). KELLY, Ernest, E.; 81 South Ward Street, New Brunswick, NJ 08901 (US). (74) Agent: STONE, Robert, L.; Colgate-Palmolive Company, 909 River Road, Piscataway, NJ 08855-1343 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 22 May 1997 (22.05.97)
(54) Title: ANTIPLAQUE ORAL COMPOSITION (57) Abstract An oral antiplaque composition and treatment of teeth therewith wherein the essential antiplaque agent is a substantially water insoluble noncationic antibacterial phenol containing, relative to the hydroxyl group, an alkyl or cycloalkyl group, preferably tert.-butyl(t-butyl), in 2-position, and substituents in one or both of the 4- and 5-positions, one of which may be phenyl or 2',3' and/or 4' substituted alkyl or cycloalkyl phenyl, preferably 4'-t-butyl phenyl, or one or both of the 4- and 5- substituents may be alkyl or cycloalkyl, one being preferably t-butyl, or a phenanthrene containing a hydroxyl substituent in the 2- or 3-positions and alkyl or cycloalkyl, preferably t-butyl, substituents in the other of the 2- and 3-positions and in at least one of the other rings. Novel antibacterial alkylated phenols.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

Int. onal Application No.

PCT/US 96/15017

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/16 C07C39/06 C07C39/12 C07C39/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 10992 A (PROCTER & GAMBLE) 9 July 1992 see page 2, line 30 - page 3, line 25 see page 5, line 29 see page 7, line 8 - page 8, line 23 see page 9, line 2 - line 33 see page 10, line 35 - page 11, line 27	1, 19-26, 34, 35, 39-41
Y		
A	see page 5, line 23 ---	27, 28 1, 7-14
X	FR 2 128 026 A (SOREDEV) 20 October 1972 see page 1, line 1 - line 16 see page 5, line 23 - page 6, line 6 --- -/-	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

1 April 1997

Date of mailing of the international search report

1 6. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (- 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (- 31-70) 340-3016

Authorized officer

McConnell, C

INTERNATIONAL SEARCH REPORT

Int. l. Application No.
PCT/US 96/15017

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 188 821 A (GAFFAR ABDUL ET AL) 23 February 1993 cited in the application see column 2, line 25 - line 33 see column 5, line 4 - column 7, line 47 ---	27,28
A	CH 553 142 A (BUREAU D'ETUDES THERAPEUTIQUES) 30 August 1974 see column 3, line 15 - line 20 see column 6, line 18 - line 22 ---	1
A	CHEMICAL ABSTRACTS, vol. 93, no. 17, 27 October 1980 Columbus, Ohio, US; abstract no. 162715, AJINOMOTO CO.: "Alkylphenols in volatile antimicrobial compositions" XP002020390 see abstract & JP 55 076 802 A ---	1,2
A	DATABASE WPI Section Ch, Week 9005 Derwent Publications Ltd., London, GB; Class B05, AN 90-033362 XP002028539 & JP 01 311 018 A (SHISEIDO KK) , 15 December 1989 see abstract ---	1,42
A	AT 302 272 A (SANDOZ) 10 October 1972 see page 5, line 1 - line 5 ---	42-46
A	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 76, 1954, EASTON, PA., pages 2357-2362, XP002028536 BRADSHER ET AL.: "Synthesis and fungistatic activity of some 3-hydroxybiphenyl derivatives." see page 2359; table 2 ---	1,7, 42-44
A	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 112, 1990, EASTON, PA., pages 8617-8618, XP002028537 HUFFMAN ET AL.: "Insertion of indenyl cobalt (I) into cyclobutenones: the first synthesis of phenols from isolated vinylketene complexes." see page 8617; table 2 ---	42
	-/--	

INTERNATIONAL SEARCH REPORT

Int ional Application No
PCT/US 96/15017

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MACROMOLECULES, vol. 4, no. 4, 1971, WASHINGTON, D.C., pages 363-369, XP000646398 PRICE ET AL.: "Some studies of oxidative coupling of phenols." see page 364; figure 9 ---	42
A	PHYTOCHEMISTRY, vol. 22, no. 4, 1983, GB, pages 1011-1015, XP000646538 SHUZO TAGAKI ET AL.: "Antimicrobial agents from 'bletilla striata' " see page 1011; figure 1 ---	42
A	TETRAHEDRON, vol. 49, no. 16, 1993, OXFORD, pages 3425-3432, XP002028538 DELLA GRECA ET AL.: "Cytotoxic 9,10 Dihydrophenanthrenes from 'Juncus effusus L.' " see figures 1-9,15-17 -----	42

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 15017

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1) Claim 1 compound II, claims 2-6 and 19-41; di- or trialkyl phenol
- 2) Claim 1 compound I, claims 7-14, claim 42 compound IV, claims 43-47 and 19-41; substituted phenyl phenol.
- 3) Claim 1 compound III, claims 15-18, claim 42 compound III, 48-50 and 19-41; substituted dihydrophenanthrol.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claim 1 compound II, claims 2-6 and 19-41 where they relate to claim 1 compound II

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In: International Application No

PCT/US 96/15017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9210992 A	09-07-92	AU 9179791 A	22-07-92
FR 2128026 A	20-10-72	NONE	
US 5188821 A	23-02-93	US 4894220 A	16-01-90
		US 5043154 A	27-08-91
		AT 398034 B	25-08-94
		AT 296789 A	15-01-94
		AT 397765 B	27-06-94
		AT 296889 A	15-11-93
		AU 632776 B	14-01-93
		AU 4676889 A	05-07-90
		AU 625379 B	09-07-92
		AU 4676989 A	05-07-90
		AU 637777 B	10-06-93
		AU 4677189 A	28-02-91
		BE 1004366 A	10-11-92
		BE 1006029 A	26-04-94
		BE 1005904 A	08-03-94
		BE 1007179 A	18-04-95
		CA 2006707 A	25-02-91
		CA 2006713 A	29-06-90
		CA 2006717 A	29-06-90
		CH 679674 A	31-03-92
		CH 679741 A	15-04-92
		CH 679639 A	31-03-92
		CZ 8907511 A	14-02-96
		DE 3942641 A	28-02-91
		DE 3942642 A	30-08-90
		DE 3942643 A	05-07-90
		EG 19073 A	30-06-94
		EG 19074 A	31-03-96
		FI 946119 A	28-12-94
		FR 2651235 A	01-03-91
		FR 2641186 A	06-07-90
		FR 2641187 A	06-07-90
		FR 2681529 A	26-03-93
		FR 2684550 A	11-06-93
		GB 2227660 A,B	08-08-90
		GB 2235201 A,B	27-02-91

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/15017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5188821 A		GB 2227661 A,B	08-08-90
		GB 2257362 A,B	13-01-93
		GB 2259856 A,B	31-03-93
		GR 1001522 B	28-02-94
		GR 1000848 B	17-02-93
		GR 89100853 A	15-03-91
		HK 154796 A	23-08-96
		HK 154896 A	23-08-96
		HK 154996 A	23-08-96
		HK 172095 A	17-11-95
		HU 212183 B	28-03-96
		IE 63176 B	22-03-95
CH 553142 A	30-08-74	IE 65326 B	18-10-95
		IE 65678 B	15-11-95
		FR 2165741 A	10-08-73
		DE 2263126 A	12-07-73
		JP 48072159 A	29-09-73
AT 302272 A	15-09-72	OA 4284 A	31-12-79
		CH 558342 A	31-01-75
		BE 737632 A	18-02-70
		DE 1943230 A	30-07-70
		FR 2016496 A	08-05-70
		GB 1275662 A	24-05-72
		KE 2570 A	24-10-75
		NL 6912869 A	03-03-70
		SE 367187 B	20-05-74
		US 3901955 A	26-08-75
		US 3707565 A	26-12-72